Non-Covalent BTK Drug Wins Broad Approval in Most Common Leukemia
(MedPage Today) -- The FDA on Friday expanded the approval of pirtobrutinib (Jaypirca) in chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) to include the first-line treatment of adults whose cancers have no known 17p deletion...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.